Antiviral agents

A copolymer of 2-(dimethylamino)ethyl methacrylate and ethyl methacrylate addresses the limitations of existing antiviral agents by effectively inhibiting enveloped viruses, offering broad-spectrum protection in diverse applications.

JP7592951B2Active Publication Date: 2024-12-03FUAN KERU +1
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2020147171
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-09-01
Publication Date
2024-12-03
Estimated Expiration
2040-09-01

AI Technical Summary

Technical Problem

Existing antiviral agents are limited in their effectiveness against enveloped viruses such as influenza and the new coronavirus, and there is a need for a novel antiviral agent with improved antiviral properties.

Method used

A copolymer composed of 2-(dimethylamino)ethyl methacrylate and ethyl methacrylate, with specific mass proportions and molecular weight, is used as an active ingredient, providing an antiviral agent effective against enveloped viruses.

Benefits of technology

The copolymer demonstrates significant antiviral activity, suppressing virus proliferation and can be incorporated into various products for broad-spectrum antiviral protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007592951000001
    Figure 0007592951000001
  • Figure 0007592951000002
    Figure 0007592951000002
  • Figure 0007592951000003
    Figure 0007592951000003
Patent Text Reader

Abstract

To provide an antiviral agent having an excellent gloss imparting effect.SOLUTION: An antiviral agent contains a copolymer having a (2-dimethylaminoethyl) methacrylate-derived constitutional unit (A) and a methethyl acrylate-derived constitutional unit (B), wherein, relative to 100 mass% of all the constitutional units, the percentage of the constitutional unit (A) is 50-95 mass%, the percentage of the constitutional unit (B) is 5-50 mass%, and the percentage of constitutional units derived from other monomers is less than 5 mass%, with a weight average molecular weight of 20,000-50,000.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an antiviral agent. [Background technology]

[0002] Various antiviral agents have been proposed to prevent infection with viruses such as influenza and the new coronavirus. For example, Patent Document 1 proposes an antiviral agent containing silica having a mesoporous structure as an active ingredient. Patent Document 2 proposes a technology in which water or an aqueous liquid is brought into contact with silica having a mesoporous structure carrying platinum to obtain water or an aqueous liquid having an antiviral effect. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] JP 2019-151598 A [Patent Document 2] JP 2020-000953 A Summary of the Invention [Problem to be solved by the invention]

[0004] An objective of the present invention is to provide a novel antiviral agent. [Means for solving the problem]

[0005] The main means for solving the problems of the present invention are as follows. 1. Having a structural unit (A) derived from 2-(dimethylamino)ethyl methacrylate represented by the following formula (1) and a structural unit (B) derived from ethyl methacrylate represented by the following formula (2), the proportion of the structural unit (A) is 50 to 95 mass%, the proportion of the structural unit (B) is 5 to 50 mass%, and the proportion of structural units derived from other monomers is less than 5 mass%, relative to 100 mass% of all structural units; 1. An antiviral agent comprising a copolymer having a weight-average molecular weight of 20,000 to 50,000. [ka] [ka] 2. The antiviral agent according to 1, wherein the target virus is an enveloped virus. 3. The antiviral agent according to 1 or 2, wherein the target virus is an influenza virus. Effect of the Invention

[0006] According to the present invention, an antiviral agent can be provided. The antiviral agent of the present invention can be used alone or in combination with other compounds to form compositions such as cosmetics, oral care products, soaps, etc. having antiviral activity. In the present invention, the antiviral effect refers to the effect of suppressing or reducing the proliferation of viruses. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] The present invention relates to an antiviral agent containing, as an active ingredient, a copolymer (INCI name: (acrylates / dimethylaminoethyl methacrylate) copolymer) of a structural unit (A) derived from 2-(dimethylamino)ethyl methacrylate represented by the following formula (1) and a structural unit (B) derived from ethyl methacrylate represented by the following formula (2).

[0008] [ka] [ka]

[0009] The antiviral agent of the present invention contains a copolymer having a structural unit (A) derived from 2-(dimethylamino)ethyl methacrylate and a structural unit (B) derived from ethyl methacrylate, This copolymer contains, relative to 100% by mass of all structural units, the proportion of structural units (A) derived from 2-(dimethylamino)ethyl methacrylate is 50 to 95 mass%, the proportion of structural units (B) derived from ethyl methacrylate is 5 to 50 mass%, and the proportion of structural units derived from other monomers is less than 5 mass%, The weight average molecular weight is 20,000 to 50,000.

[0010] <About the copolymer> The proportion of the structural unit (A) relative to 100% by mass of all structural units in the copolymer is 50 to 95% by mass, preferably 50 to 85% by mass, more preferably 50 to 75% by mass, and even more preferably 55 to 65% by mass. The proportion of the structural unit (B) relative to 100% by mass of all structural units in the copolymer is 5 to 50% by mass, preferably 15 to 50% by mass, more preferably 25 to 50% by mass, and even more preferably 35 to 45% by mass. In this specification, the expression "A to B" (A and B are numerical values) indicates a range that includes A and B.

[0011] The copolymer of the present invention may have a structural unit (e) derived from another monomer (E) other than the structural unit (A) derived from 2-(dimethylamino)ethyl methacrylate and the structural unit (B) derived from ethyl methacrylate. The other monomer (E) is not particularly limited as long as it can be copolymerized with 2-(dimethylamino)ethyl methacrylate and ethyl methacrylate.

[0012] Examples of the monomer that can be used as the monomer (E) are given below. For example, there is an unsaturated monocarboxylic acid (salt), such as (meth)acrylic acid (salt). For example, alkyl (meth)acrylates can be mentioned as esters of (meth)acrylic acid and alkyl alcohols. In this case, the alkyl group may have a straight-chain structure or a branched structure, and preferably has 1 to 12 carbon atoms. For example, the above-mentioned (meth)acrylate esters of (meth)acrylic acid and alcohols may have a substituent, such as a hydroxyl group, an alkoxy group, an oxyalkylene group, or a sulfone group. For example, a monomer having two or more ethylenically unsaturated groups may be included. Examples of the polyol include esters of di- or more substituted hydroxyl groups of polyols such as ethylene glycol, propylene glycol, sorbitol, and 1,4-butanediol with (meth)acrylic acid; and ethers of di- or more substituted hydroxyl groups of the above polyols with unsaturated alcohols such as allyl alcohol and vinyl alcohol. These other monomers may be used alone or in combination of two or more kinds.

[0013] The antiviral agent of the present invention is provided as an additive intended to impart an antiviral effect, and is also provided as a composition for daily necessities such as laundry detergents and fabric softeners, topical skin preparations, cosmetics, quasi-drugs, pharmaceuticals, and the like intended to impart an antiviral effect. The antiviral agent of the present invention can be produced according to a commonly used formulation method, and can be made into solution-like, emulsion-like, or polymer gel-like preparations such as lotions, milky lotions, creams, and gels, as well as foam-like preparations, multi-layered preparations, spray preparations, sheets impregnated into nonwoven fabrics, or gel pack preparations.

[0014] The antiviral agent of the present invention may contain oils and fats such as vegetable oils, higher fatty acids, higher alcohols, silicones, anionic surfactants, cationic surfactants, amphoteric surfactants, nonionic surfactants, preservatives, sugars, sequestering agents, polymers such as water-soluble polymers, thickeners, powder components, ultraviolet absorbers, ultraviolet blocking agents, moisturizers such as hyaluronic acid, fragrances, pH adjusters, etc. It may also contain other medicinal and physiologically active ingredients such as vitamins, skin activators, blood circulation promoters, resident flora control agents, active oxygen scavengers, anti-inflammatory agents, whitening agents, and bactericides.

[0015] The concentration of the copolymer of 2-(dimethylamino)ethyl methacrylate and ethyl methacrylate in the antiviral agent of the present invention is not particularly limited as long as it is within a range in which an antiviral effect can be expected, but the lower limit of the concentration is preferably 0.0001% by mass or more, more preferably 0.001% by mass or more, based on the total mass% of the antiviral agent. The upper limit of the concentration is preferably 30% by mass or less, more preferably 10% by mass or less, based on the total mass% of the antiviral agent.

[0016] The target viruses of the antiviral agent of the present invention are not particularly limited, and specific examples thereof include enveloped viruses such as influenza virus, coronavirus, herpes virus, RS virus, rubella virus, measles virus, varicella-zoster virus, flavivirus, rhabdovirus, etc., and non-enveloped viruses (viruses without an envelope) such as norovirus, rotavirus, human papillomavirus, adenovirus, enterovirus, etc. Among these, preferred are enveloped viruses, and more preferred are influenza viruses. EXAMPLES

[0017] The present invention will be described in detail below based on examples, but the present invention is not limited to these.

[0018] <Gel Permeation Chromatography (GPC)> The weight average molecular weight (Mw) of the copolymer was measured by gel permeation chromatography (GPC) under the following conditions and apparatus: Equipment: Waters e2695 Detector: Differential Refractometer (RI) detector Column: Tosoh TSKgel α-M, α-2500 Column temperature: 40℃ Flow rate: 0.8mL / min Injection volume: 10 μL (eluent preparation solution with sample concentration of 0.4 wt%) Calibration curve: Polyethylene glycol manufactured by GL Sciences GPC software: Waters EMPOWER3 Eluent: 0.5M acetic acid + 0.2M Na nitrate / acetonitrile = 50 / 50 (v / v)

[0019] <Confirmation test of antiviral effect> As the copolymer of 2-(dimethylamino)ethyl methacrylate and ethyl methacrylate of the present invention (INCI name: (acrylates / dimethylaminoethyl methacrylate) copolymer, a mixture of 37.9 mass% of a copolymer having a molecular weight of about 30,000 (hereinafter, copolymer (1)) containing about 60 mass% of 2-(dimethylamino)ethyl methacrylate and about 40 mass% of ethyl methacrylate relative to 100 mass% of all structural units, 19.6 mass% of butylene glycol, and 42.5 mass% of water was used, and the mixture was diluted with water to a copolymer concentration of 0.038 mass% to prepare a test liquid. As comparative examples, a 5% by weight aqueous solution of Polyquaternium-51 (Lipidure (registered trademark)-PMB, NOF Corporation) was diluted with water to a polymer concentration of 0.038% by weight, and a 70 vol% aqueous ethanol solution were used as test liquids, and PBS (phosphate buffered saline) was used as a control.

[0020] Influenza A virus (H3N2) A / Hong Kong / 8 / 68 strain (influenza A virus, ATCC VR-1679) was infected into host cells, MDCK cells (ATCC CCL-34), and the culture supernatant was diluted 100-fold with phosphate buffered saline (PBS) to obtain a test virus solution. Antiviral tests were performed according to ASTM E1052 - Standard test method for evaluating the activity of disinfectants against viruses in suspension. (Antiviral test) 0.9 ml of the test solution and 0.1 ml of the test virus solution were mixed and left to stand at room temperature for 10 minutes. Then, 9.0 ml of SCDLP was added to prepare a 10-fold dilution series, which was then added to the host cells, MDCK cells (ATCC CCL-34), and cultured. The virus infectivity after the action (TCID50 (50% Tissue Culture Infectious Dose)) was calculated by the plaque method. (Antiviral activity value) The antiviral activity value was calculated according to the following formula. Antiviral activity value=Log(virus infectivity of control)−Log(virus infectivity of example or comparative example)

[0021] [Table 1]

[0022] It was confirmed that Example 1 of the present invention had an antiviral activity value of greater than 1.0 and thus had an antiviral effect.

[0023] (Formulation example 1) Lotion Copolymer (1) 1% 1,3-Butylene glycol 6% Glycerin 4% Dipropylene glycol 1% Sorbitol 1% Citric acid 0.1% Ethanol 5% water residue

[0024] (Formulation example 2) Cream Copolymer (1) 1% Squalane 9% Vaseline 5% Stearic acid 2% Behenyl alcohol 3% 1,3-Butylene glycol 6% Sorbitol 1% Glyceryl monostearate 2% POE(20) Sorbitan monooleate 2% water residue

Claims

1. The copolymer has a structural unit (A) derived from 2-(dimethylamino)ethyl methacrylate represented by the following formula (1) and a structural unit (B) derived from ethyl methacrylate represented by the following formula (2), the proportion of the structural unit (A) is 55 to 65 mass%, the proportion of the structural unit (B) is 35 to 45 mass%, and the proportion of structural units derived from other monomers is less than 5 mass%, based on 100 mass% of all structural units; Contains a copolymer having a weight average molecular weight of 20,000 to 50,000, 1. An antiviral agent characterized by being used for imparting antiviral properties to any of daily necessities, topical skin preparations, cosmetics, and quasi-drugs. 【Chemistry 1】 【Chemistry 2】

2. 2. The antiviral agent according to claim 1, wherein the target virus is an enveloped virus.

3. 3. The antiviral agent according to claim 1 or 2, wherein the target virus is an influenza virus.

4. An antiviral agent according to any one of claims 1 to 3, characterized in that it contains butylene glycol or ethanol.

5. A daily household item, topical skin preparation or cosmetic comprising a virus agent according to any one of claims 1 to 4.

6. The daily product, skin topical agent or cosmetic preparation as described in Claim 5, characterized in that it is any one of a lotion, milky lotion, cream, gel, emulsion, polymer gel preparation, foam preparation, multi-layer preparation, spray preparation, sheet impregnated in nonwoven fabric, and gel pack preparation.

Citation Information

Patent Citations

  • Pharmaceutical composition

    JP2015193560A

  • Method of producing organoxysilane compound having imine structure

    JP2019151598A

  • Aqueous liquid

    JP2020000953A

  • Antifungal agent

    JP2020079239A